Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.

Michael T DolingerElizabeth A SpencerJoanne LaiDavid DunkinMarla C Dubinsky

Published in: Inflammatory bowel diseases (2022)

Our data suggest that dual therapy may be an option for patients with limited therapeutic options remaining. Safety concerns should always be at the forefront of decision-making, and larger studies are needed to help confirm the preliminary safety data observed.

Keyphrases

small molecule
decision making
electronic health record
big data
rheumatoid arthritis
stem cells
artificial intelligence
machine learning
data analysis
bone marrow
deep learning
ulcerative colitis
smoking cessation